-
New NIH Analysis Links PFAS ‘Forever Chemicals’ to Increased Aggressive Breast Cancer Risk
Understanding the Link Between PFAS and Breast Cancer A recent analysis conducted by the National Institutes of Health (NIH) has shed light on a concerning potential health risk regarding PFAS (per- and polyfluoroalkyl substances), often referred to as ‘forever chemicals.’ These synthetic substances, known for their persistence in the environment and the human body, have…
-
A $10 Million Breakthrough: Researching the Roots of Breast Cancer Relapse
Advancing the Fight Against Cancer The Montefiore Einstein Comprehensive Cancer Center (MECCC) has received a significant $10 million grant to tackle one of the most persistent challenges in oncology: breast cancer relapse. This substantial funding aims to fuel cutting-edge research into why breast cancer can return, often years after initial treatment. The Mission: Decoding Dormancy…
-
New Hope for Advanced Breast Cancer: FDA Grants Accelerated Approval to Etcamah
A Significant Milestone in Oncology The landscape of breast cancer treatment has seen a notable advancement with the FDA’s recent decision to grant accelerated approval to Etcamah (camizestrant). This new therapy is specifically indicated for use in combination with a CDK4/6 inhibitor for the treatment of patients with advanced or metastatic hormone receptor (HR)-positive, HER2-negative…
-
New Hope: FDA Approves Pfizer’s Tukysa Regimen for Metastatic Breast Cancer
NYSE: $PFE A Significant Milestone in Oncology The landscape of breast cancer treatment has shifted once again as the FDA has officially granted approval for a new regimen involving Pfizer’s Tukysa (tucatinib). This approval marks a critical step forward for patients battling HER2-positive metastatic breast cancer, particularly in the front-line maintenance setting. Understanding the New…
-
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
South San Francisco, CA — September 30, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with… Source: Read More
-
New Hope: FDA Approves Inluriyo (Imlunestrant) Combination for Advanced Breast Cancer
NYSE: $LLY A New Frontier in Targeted Cancer Therapy The landscape of breast cancer treatment has taken a significant step forward with the recent FDA approval of Inluriyo (imlunestrant). This novel medication, used in combination with Verzenio (abemaciclib), offers a new targeted approach for specific patient populations battling advanced or metastatic breast cancer. Understanding the…
-
New Clinical Data: Camizestrant Shows Promise in Advanced Breast Cancer Treatment
A Significant Milestone for Advanced Breast Cancer Recent clinical trial results have brought a wave of optimism for patients battling ER-positive, HER2-negative advanced breast cancer. Data concerning Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), has demonstrated a meaningful impact on disease progression when used in combination therapies. Understanding the Trial Outcomes The findings…